AU2004292416B2 - Method of decreasing fat deposits and body weight in mammals and birds - Google Patents

Method of decreasing fat deposits and body weight in mammals and birds Download PDF

Info

Publication number
AU2004292416B2
AU2004292416B2 AU2004292416A AU2004292416A AU2004292416B2 AU 2004292416 B2 AU2004292416 B2 AU 2004292416B2 AU 2004292416 A AU2004292416 A AU 2004292416A AU 2004292416 A AU2004292416 A AU 2004292416A AU 2004292416 B2 AU2004292416 B2 AU 2004292416B2
Authority
AU
Australia
Prior art keywords
salbutamol
isomer
mammal
beta
bird
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004292416A
Other languages
English (en)
Other versions
AU2004292416A1 (en
Inventor
Gunnar A. K. Aberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALTERAGON Pty Ltd
Original Assignee
ALTERAGON Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALTERAGON Pty Ltd filed Critical ALTERAGON Pty Ltd
Publication of AU2004292416A1 publication Critical patent/AU2004292416A1/en
Application granted granted Critical
Publication of AU2004292416B2 publication Critical patent/AU2004292416B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
AU2004292416A 2003-11-20 2004-11-12 Method of decreasing fat deposits and body weight in mammals and birds Ceased AU2004292416B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US52437603P 2003-11-20 2003-11-20
US60/524,376 2003-11-20
PCT/US2004/037966 WO2005051092A2 (en) 2003-11-20 2004-11-12 Method of decreasing fat deposits and body weight in mammals and birds
US10/987,665 US20050113456A1 (en) 2003-11-20 2004-11-12 Method of decreasing fat deposits and body weight in mammals and birds
US10/987,665 2004-11-12

Publications (2)

Publication Number Publication Date
AU2004292416A1 AU2004292416A1 (en) 2005-06-09
AU2004292416B2 true AU2004292416B2 (en) 2010-01-28

Family

ID=34595131

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004292416A Ceased AU2004292416B2 (en) 2003-11-20 2004-11-12 Method of decreasing fat deposits and body weight in mammals and birds

Country Status (8)

Country Link
US (2) US20050113456A1 (https=)
EP (1) EP1684593A4 (https=)
JP (1) JP2007515402A (https=)
AU (1) AU2004292416B2 (https=)
CA (1) CA2545559A1 (https=)
NZ (1) NZ547178A (https=)
WO (1) WO2005051092A2 (https=)
ZA (1) ZA200604077B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615173C (en) 2005-07-14 2012-01-03 Lipothera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
US20070264313A1 (en) * 2006-05-12 2007-11-15 Musser Robert E Methods and compositions relating to animal dietary acids
JP2010506941A (ja) * 2006-10-17 2010-03-04 リセラ，インク． 甲状腺眼症の治療のための方法、組成物及び製剤
WO2009073051A1 (en) * 2007-12-03 2009-06-11 Bridge Pharma, Inc. Use of rr/sr-ractopamine
WO2010027259A1 (en) 2008-09-02 2010-03-11 N.V. Nutricia Nutritional compositions with coated lipid globules
WO2010068086A1 (en) 2008-12-11 2010-06-17 N.V. Nutricia Nutritional compositions with large lipid globule size
US9132084B2 (en) * 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
GB2487868B (en) * 2010-01-15 2014-12-10 Neothetics Inc Lyophilized cake formulations
WO2011115476A1 (en) 2010-03-17 2011-09-22 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes later in life
UA111822C2 (uk) * 2010-11-24 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Новамедіка" Монотерапевтичий препарат селективного ліпофільного бета-агоніста тривалої дії і спосіб косметичного лікування ожиріння і контурного випинання
ES2693519T3 (es) 2013-11-01 2018-12-12 N.V. Nutricia Composición lipídica para mejorar la composición corporal durante el crecimiento de recuperación
KR102273533B1 (ko) * 2015-06-15 2021-07-06 삼성전자 주식회사 무선 통신 시스템에서 서비스 제공 방법 및 장치
WO2017064304A1 (en) 2015-10-15 2017-04-20 N.V. Nutricia Infant formula with special lipid architecture for promoting healthy growth
ES2987545T3 (es) 2016-12-09 2024-11-15 Nutricia Nv Composición nutricional para su uso en la mejora del rendimiento cognitivo y/o la prevención del deterioro cognitivo

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2186796A (en) * 1986-02-19 1987-08-26 Glaxo Group Ltd Veterinary preparations containing salbutamol

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0085514A3 (en) * 1982-01-28 1984-02-29 Beecham Group Plc Compositions comprising a beta-antagonist and a beta-agonist, their preparation, and their use in treating obese humans and animals
IE60964B1 (en) * 1986-12-11 1994-09-07 Roussel Uclaf Zootechnical compositions containing a beta-adrenergic
US5147869A (en) * 1986-12-11 1992-09-15 Roussel Uclaf Zootechnical compositions
US5541188A (en) * 1987-09-15 1996-07-30 The Rowett Research Institute Therapeutic applications of beta-adrenergic agonists
US5530029A (en) * 1987-09-15 1996-06-25 The Rowett Research Institute Therapeutic applications of clenbuterol
FR2642075B1 (fr) * 1989-01-25 1991-04-26 Pasteur Institut Polypeptides ayant une activite de recepteur (beta)-adrenergique chez l'homme, impliques dans la reponse lipolytique, acides nucleiques codant pour ces polypeptides et utilisation de ces polypeptides pour le criblage de substance active sur ces polypeptides
DK339289D0 (da) * 1989-07-07 1989-07-07 Dak Lab As Farmaceutisk praeparat
JP3085705B2 (ja) * 1990-01-05 2000-09-11 セプラカー・インコーポレーテツド 喘息の治療のための光学的純粋ｒ（−）アルブテロール
US5362755A (en) * 1990-01-05 1994-11-08 Sepracor, Inc. Method for treating asthma using optically pure (R)-albuterol
JP3358631B2 (ja) * 1993-05-17 2002-12-24 三菱瓦斯化学株式会社 メタノ−ルの脱水素方法
US5399765A (en) * 1994-05-23 1995-03-21 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
US5545745A (en) * 1994-05-23 1996-08-13 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
US5698199A (en) * 1995-03-10 1997-12-16 Kao Corporation Lipolysis acceleration method
US5708036A (en) * 1996-01-29 1998-01-13 Pesterfield, Jr.; E. Charles Method of treating premature uterine contractions using the optically active R(-)-isomer of albuterol
CA2286913C (en) * 1997-04-30 2008-12-09 Bridge Pharma, Inc. Composition and methods using an eutomer
US7767708B2 (en) * 1998-11-04 2010-08-03 Schering-Plough Animal Health Corp. Growth stimulant compositions
US6683115B2 (en) * 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
GB0030171D0 (en) * 2000-12-11 2001-01-24 Cipla Ltd Process for preparing isomers of salbutamol

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2186796A (en) * 1986-02-19 1987-08-26 Glaxo Group Ltd Veterinary preparations containing salbutamol

Also Published As

Publication number Publication date
US20050113456A1 (en) 2005-05-26
ZA200604077B (en) 2009-11-29
EP1684593A4 (en) 2010-02-10
EP1684593A2 (en) 2006-08-02
WO2005051092A3 (en) 2006-04-06
CA2545559A1 (en) 2005-06-09
JP2007515402A (ja) 2007-06-14
WO2005051092A2 (en) 2005-06-09
AU2004292416A1 (en) 2005-06-09
NZ547178A (en) 2008-06-30
US20080020019A1 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
US20080020019A1 (en) Method of decreasing fat deposits and body weight in mammals and birds
AU2008331928B2 (en) Use of RR/SR-ractopamine
US8445542B2 (en) Methods of accelerating muscle growth, decreasing fat deposits and improving feed efficiency in livestock animals
CA2039194C (en) Uses of l-deprenyl and compositions for same
AU737608B2 (en) Composition and methods using an eutomer
JP2007515402A5 (https=)
EP0662324A1 (en) Use of beta-adrenergic agonists for treating loss of function of striated muscles
JP6209208B2 (ja) ブロイラー鶏の性能向上法
US20080070990A1 (en) Use of ractopamine enantiomers
CN109068685B (zh) 含有日香木苷和/或夜香树苷的动物饲料添加剂
EP1787529A2 (en) Composition and methods using an eutomer
MXPA99009783A (en) Composition and methods using an eutomer
CN1882320A (zh) 减少哺乳动物和鸟类的脂肪堆积物和体重的方法
WO2009020620A1 (en) Synergisms between repartitioning and immunomodulating compounds
THEJOMOORTHY STUDIES ON THE EFFECT OF CERTAIN GROWTH PROMOTING AGENTS IN RABBITS FOR MEAT AND WOOLf HAIR PRODUCTION
HK1011611B (en) Use of l-deprenyl for retarding age dependent deterioration of the immune system function in mammals

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired